Histogenics Corporation (HSGX)’s Financial Results Comparing With Replimune Group Inc. (NASDAQ:REPL)

Histogenics Corporation (NASDAQ:HSGX) and Replimune Group Inc. (NASDAQ:REPL) are two firms in the Biotechnology that compete against each other. Below is a comparison of their dividends, analyst recommendations, profitability, risk, institutional ownership, earnings and valuation.

Valuation and Earnings

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Histogenics Corporation N/A 0.00 8.52M -0.43 0.00
Replimune Group Inc. N/A 0.00 31.03M -0.99 0.00

We can see in table 1 the earnings per share (EPS), top-line revenue and valuation of Histogenics Corporation and Replimune Group Inc.

Profitability

Table 2 provides us Histogenics Corporation and Replimune Group Inc.’s return on equity, return on assets and net margins.

Net Margins Return on Equity Return on Assets
Histogenics Corporation 0.00% 66.4% -73.3%
Replimune Group Inc. 0.00% -54.8% -28.8%

Liquidity

Histogenics Corporation’s Current Ratio and Quick Ratio are 0.7 and 0.7 respectively. The Current Ratio and Quick Ratio of its competitor Replimune Group Inc. are 38.1 and 38.1 respectively. Replimune Group Inc. therefore has a better chance of paying off short and long-term obligations compared to Histogenics Corporation.

Analyst Ratings

In next table is given Histogenics Corporation and Replimune Group Inc.’s ratings and recommendations.

Sell Ratings Hold Ratings Buy Ratings Rating Score
Histogenics Corporation 0 1 0 2.00
Replimune Group Inc. 0 0 0 0.00

Institutional and Insider Ownership

The shares of both Histogenics Corporation and Replimune Group Inc. are owned by institutional investors at 16.1% and 56.8% respectively. 9.2% are Histogenics Corporation’s share owned by insiders. On the other hand, insiders owned about 0.3% of Replimune Group Inc.’s shares.

Performance

In this table we show the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Histogenics Corporation -9.33% -42.55% -77.87% -95.35% -95.4% 35.18%
Replimune Group Inc. 0.69% 7.68% -13.07% -36.51% 0% 30.4%

For the past year Histogenics Corporation’s stock price has bigger growth than Replimune Group Inc.

Summary

Histogenics Corporation beats Replimune Group Inc. on 5 of the 7 factors.

Histogenics Corporation, a regenerative medicine company, focuses on developing and commercializing products in the musculoskeletal segment of the marketplace in the United States. The company offers NeoCart, a tissue implant, which is in Phase III clinical trial to treat tissue injury in the field of orthopedics, specifically cartilage damage in the knee. It has an exclusive channel collaboration agreement with Intrexon Corporation for the development and commercialization of allogeneic genetically modified chondrocyte cell therapeutics for the treatment or repair of damaged articular hyaline cartilage in humans. Histogenics Corporation was founded in 2000 and is headquartered in Waltham, Massachusetts.

Replimune Group, Inc., a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company uses its proprietary Immulytic platform to design and develop product candidates that are intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of herpes simplex virus 1 that is in Phase I/II clinical trials for a range of solid tumors. The company is also developing RP2, which is in Preclinical trials to express an anti-CTLA-4 antibody-like protein in order to block the inhibition of the immune response otherwise caused by CTLA-4; and RP3 that is in Preclinical trials to express immune-activating proteins that stimulate T cells. Replimune Group, Inc. was founded in 2015 and is headquartered in Woburn, Massachusetts.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.